Status:

Do Not Prescribe (DNP), Red

Decision Date:

March 2019

Comments

RED: Prophylaxis of CMV reactivation and disease in adult AMV-seropositive recipients of an allogenic haematopoietic stem cell transplant

RED: NICE TA591 - for preventing cytomegalovirus disease after stem cell transplant. (Decision date - August 2019)

 DNP: NICE TA1082 (Terminated appraisal) Letermovir for preventing cytomegalovirus infection after a kidney transplant (Decision date Aug 2025)

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again